Emerging cognitive enhancing drugs

Expert Opinion on Emerging Drugs

Volumn 14, Issue 4, 2009, Pages 577-589

  Buccafusco, Jerry J ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Allosteric modulators; Cognition; Dimebolin; Donepezil; Drug development; GTS 21; Ladostigil; Memantine; Memory; Neurotransmitter receptors

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; ABT 560; AV 965; AZD 0328; CHOLINESTERASE INHIBITOR; CX 1739; CX 717; DIMEBON; DONEPEZIL; EVP 0334; GALANTAMINE; LADOSTIGIL; MCD 386; MEM 3454; MEM 63908; MEMANTINE; MIMOPEZIL; N [2 [4' (2 METHYLSULFONAMIDOETHYL)BIPHENYL 4 YL]PROPYL] 2 PROPANESULFONAMIDE; NP 0361; PHENSERINE; PRX 03140; PRX 07034; RIVASTIGMINE; SAM 315; SAM 531; SYN 114; SYN 120; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANOREXIA; BRADYCARDIA; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COST OF ILLNESS; DEGENERATIVE DISEASE; DIARRHEA; DRUG MARKETING; DRUG MECHANISM; GASTROINTESTINAL DISEASE; HUMAN; NAUSEA; NONHUMAN; REVIEW;

AGING; ANIMALS; ANTIOXIDANTS; COGNITION; COGNITION DISORDERS; COST OF ILLNESS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; MEMORY; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIC PSYCHOLOGY;

EID: 71649108692     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903257796     Document Type: Review

References (79)

1. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006;5:965-970
2. Jellinger KA. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Frontiers Neurol Neurosci 2009;24:114-125
3. Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006;8:2061-2073
4. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007;6:994-1003 (Pubitemid 47562321)
5. Joyce EM, Roiser JP. Cognitive heterogeneity in schizophrenia. Curr Opin Psychiat 2007;20:268-272
6. Thomas AJ, O'Brien JT. Depression and cognition in older adults. Curr Opin Psychiat 2008;21:8-13
7. Skirrow C, McLoughlin G, Kuntsi J, Asherson P. Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability. Expert Rev Neurotherapeut 2009;9(4):489-503
8. Grenard JL, Ames SL, Wiers RW, et al. Working memory capacity moderates the predictive effects of drug-related associations on substance use. Psychology Addict Behav 2008;22:426-432
9. Taggart DP, Westaby S. Neurological and cognitive disorders after coronary artery bypass grafting. Curr Opin Cardiol 2001;16:271-276
10. Poggesi A, Pantoni L. Investigations in primary care. Front Neurol Neurosci 2009;24:66-78
11. Silver JM, McAllister TW, Arciniegas DB. Depression and cognitive complaints following mild traumatic brain injury. Am J Psychiat 2009;166:653-661
12. Salthouse TA. When does age-related cognitive decline begin? Neurobiol Aging 2009;30:507-514
13. Mariani E, Monastero R, Mecocci P. Mild cognitive impairment: a systematic review. J Alzheimers Dis 2007;12:23-35
14. Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of Alzheimer's disease: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003;306:821-827
15. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 2009;6:86-96
16. Reisberg B, Doody R, Stöffler A, et al. Memantine study group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341
17. Buccafusco JJ, Terry AV Jr. Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. J Mol Neurosci 2004;24:85-91
18. Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6:4-14
19. Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007;11:491-507
20. Buccafusco JJ. Multifunctional receptor-directed drugs for disorders of the central nervous system. Neurotherapeutics 2009;6:4-13
21. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6:341-342
22. Kozikowski IP, Gaisina IN, PetukhovHighly PA, et al. Highly potent and specific GSK-3 inhibitors that block tau phosphorylation and decrease ?-synuclein protein expression in a cellular model of Parkinson's disease. Chem Med Chem 2006;1:256-266
23. Wischik CM, Edwards PC, Lai RYK. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996;93:11213-11218
24. Hooper NM, Turner AJ. The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem 2002;9:1107-1119
25. Suzuki T, Hide I, Matsubara A, et al. Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 2006;83:1461-1470
26. Li XD, Arias E, Jonnala RR, et al. Effect of amyloid peptides on the increase in TrkA receptor expression induced by nicotine in vitro and in vivo. J Mol Neurosci 2005;27:325-336
27. Lee GM, Craik CS. Trapping moving targets with small molecules. Science 2009;24:213-215
28. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54
29. Ross DA, Lee S, Reiser V, et al. Multiplexed assays by high-content imaging for assessment of GPCR activity. J Biomol Screening 2008;13:449-455
30. Klein J. Phenserine. Expert Opin Invest Drugs 2007;16:1087-1097
31. Buccafusco JJ. Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol Interventions 2004;4:285-295
32. Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006;66:408-410
33. Ren K, Puig V, Papke RL, et al. Multiple calcium channels and kinases mediate alpha7 nicotinic receptor neuroprotection in PC12 cells. J Neurochem 2005;94:926-933
34. Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Frontiers Biosci 2008;13:492-504 but only recently have the downstream mechanisms been elucidated.
35. Marrero MB, Bencherif M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res 2009;1256:1-7
36. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha 7 nicotinic agonist in schizophrenia. Arch Gen Psychiat 2006;63:630-638
37. Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008;195:30-38
38. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008;5:458-469
39. Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of ?-amyloid peptides and increases neuronal survival. Exp Neurol 2007;203:274-278
40. Berezhnoy D, Gravielle MC, Farb DH. Pharmacology of the GABAA Receptor. In: Sibley DR, Hanin I, Kuhar M, Skolnick P, editors, Handbook of Contmporary Neuropharmacology, Hoboken NJ: John Wiley & Sons; 2007. p. 465-568
41. Lewis DA, Cho RY, Carter CS, et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiat 2008;165:1585-1593
42. Gassmann M, Bettler B. Metabotropic GABA receptors. In: Sibley DR, Hanin I, Kuhar M, Skolnick P, editors, Handbook of contmporary neuropharmacology, Hoboken NJ: John Wiley & Sons; 2007. p. 569-615
43. Froestl W, Gallagher M, Jenkins H, et al. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol 2004;68:1479-1487
44. Youdim MBH, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacological Sci 2005;26:27-35
45. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 2001;939:425-435
46. Lermontova NN, Redkozubov AE, Shevtsova EF, et al. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 2001;132:1079-1083
47. Bachurin SO, Shevtsova EP, Kireeva EG, et al. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 2003;993:334-344
48. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-215
49. Hancock AA, Fox GB. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004;13:1237-1248
50. Albuquerque EX, Santos MD, Alkondon M, et al. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15(Suppl 1):S19-25
51. Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007;11:491-507
52. Hurst RS, Hajós M, Raggenbass M, et al. A novel positive allosteric modulator of the ?7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 2005;25:4396-4405
53. Gronlien JH, Hakerud M, Ween H, et al. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 2007;72:715-724
54. Livingstone PD, Srinivasan J, Kew JN, et al. alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci 2009;29:539-550
55. Sood A, Beach JW, Webster SJ, et al. The effects of JWB1-84-1 on memory-related task performance by amyloid A? transgenic mice and by young and aged monkeys. Neuropharmacology 2007;53:588-600
56. Buccafusco JJ, Beach WJ, Terry AV Jr. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 2009;328:364-370
57. Gardoni F, Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2006;545:2-10
58. Chappell AS, Gonzales C, Williams J, et al. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007;68:1008-1012
59. Guan JS, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009;459:55-63
60. Hahnen E, Hauke J, Tränkle C, et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 2008;17:169-184
61. Wei J, Walton EA, Milici A, Buccafusco JJ. m1-m5 Muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J Neurochem 1994;63:815-821
62. Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: Implications for cholinergic-based therapies. Life Sci 1995;56:869-876
63. Mehta MA. Riedel WJ. Dopaminergic enhancement of cognitive function. Curr Pharmaceut Design 2006;12:2487-2500
64. Renerkens OAH, Rutten K, Steinbusch HSM, et al. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 2009;202:419-443
65. Haile M, Limson F, Gingrich K, et al. Nimodipine prevents transient cognitive dysfunction after moderate hypoxia in adult mice. J Neurosurg Anesthesiol 2009;21:140-144
66. Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig 2008;28:533-552
67. Schaeffer EL, Forienza OV, Gattaz WF. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer's disease. Psychopharmacology 2009;202:37-51
68. Gastambide F, Viollet C, Lepousez G, et al. Hippocampal SSTR4 somatostatin receptors control the selection of memory strategies. Psychopharmacology 2009;202:153-163
69. Gasbarri A, Pompili A, D'Onofrio A, et al. Working memory for emotional facial expressions: role of estrogen in humans and non-human primates. Rev Neurosci 2008;19:129-148
70. Black MD, Varty GB, Arad M, et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 2009;202:385-396
71. Lim WK. GPCR drug discovery: novel ligands for CNS receptors. Recent Patents CNS Drug Discov 2007;2:107-112
72. Huentelman MJ, Stephan DA, Talboom J, et al. Peripheral delivery of a ROCK inhibitor improves learning and working memory. Behav Neurosci 2009;123:218-223
73. Gard PR, Rusted JM. Angiotensin and Alzheimer's disease: therapeutic prospects. Expert Rev Neurotherapeut 2004;4:87-96
74. Gard PR. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Invest Drugs 2004;8:7-14
75. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007;6:211-219
76. Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8:203-212
77. Enna SJ, Williams M. Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Ther 2009;329:404-411
78. Faghih R, Gopalakrishnan M, Briggs CA. Allosteric modulators of the ?7 nicotinic acetylcholine receptor. J Med Chem 2008;51:701-712
79. Buccafusco JJ, Terry AV Jr. Multiple CNS targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 2000;295:438-446